#1
|
||||
|
||||
ÁÀÄÛ â ðàìêàõ ÅÂÌ?
Óâàæàåìûå äîêòîðà! Âîçìîæíû ëè ÅÂÌ-íûå äîêàçàòåëüñòâà äëÿ ÁÀäîâ? Ñåãîäíÿ óçíàë, ÷òî äîêàçàíà ýôôåêòèâíîñü Ëþòåèíà baushlomb. Ñàì íè÷åãî ïî íåìó íàéòè íå ìîãó. Ìîæåò ó êîãî-íèáóäü åñòü ññûëêè?
È åù¸, êòî-íèáóäü åãî íàçíà÷àåò? |
#2
|
|||
|
|||
Íåêîãäà ÿ ïèàðèë òàêóþ ññûëêó: [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Ýòî îòâåò íà îáùèé âîïðîñ. |
#3
|
|||
|
|||
Ðàíäîìèçèðîâàííûå èññëåäîâàíèÿ AREDS íà ðàííèõ ñòàäèÿõ ÂÌÄ, êîòîðûå ïðîâîäèëèñü â ÑØÀ íå âêëþ÷àëè ëþòåèí è çåàêñàíòèí, êîòîðûå ñîäåðæàòñÿ â îêóâàéò-ëþòåèíå.
 íàñòîÿùåå âðåìÿ âûïîëíÿåòñÿ íîâîå ðàíäîìèçèðîâàííîå êëèíè÷åñêîå èññëåäîâàíèå AREDS 2, êîòîðîå âêëþ÷àåò ëþòåèí è çåàêñàíòèí. Íî ðåçóëüòàòîâ ïîêà íåò. AREDS (Age-Related Eye Disease Study) – ñàìîå áîëüøîå èññëåäîâàíèå, â êîòîðîå ñðàâíèëè ýôôåêòèâíîñòü ïðèåìà âûñîêèõ äîç àíòèîêñèäàíòíûõ âèòàìèíîâ Ñ (500 ìã), Å (400 åäèíèö) è áåòà-êàðîòèíà (15 ìã) â êîìáèíàöèè ñ öèíêîì (80 ìã) è ìåäüþ (2 ìã) è ïëàöåáî ãðóïïîé íà ïðîòÿæåíèè 6 ëåò. |
#4
|
||||
|
||||
Åñòü è äðóãèå ïîçèòèâíûå ÐÊÈ ïî ëþòåèíó (íå òàêèå ìàñøòàáíûå è íå òàêèå ïðîäîëæèòåëüíûå êàê AREDS), íî òàêè ÐÊÈ, íàïð:
Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (Lutein Antioxidant Supplementation Trial). Richer S, Stiles W, Statkute L, Pulido J, Frankowski J, Rudy D, Pei K, Tsipursky M, Nyland J. Optometry. 2004 Apr;75(4):216-30. --- Lutein supplementation in retinitis pigmentosa: PC-based vision assessment in a randomized double-masked placebo-controlled clinical trial [NCT00029289]. Bahrami H, Melia M, Dagnelie G. BMC Ophthalmol. 2006 Jun 7;6:23. --- A 12-week lutein supplementation improves visual function in Chinese people with long-term computer display light exposure. Ma L, Lin XM, Zou ZY, Xu XR, Li Y, Xu R. Br J Nutr. 2009 Jul;102(2):186-90.
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#5
|
|||
|
|||
Öèòàòà:
À âñå îñòàëüíîå ñ÷èòàþ âòîðîñòåïåííûì. Èíôîðìèðóþ î ïîëîæèòåëüíîé ñòîðîíå ïðèìåíåíèÿ ÎÌÅÃÀ-3, Âèòðóì Âèçèîí (âèòðóìîâñêèé àíàëîã Îêóâàéòà), ñîîáùàþ î ïîëüçå óïîòðåáëåíèÿ ðûáû è ò.ä. è.ò.ï. |
#6
|
||||
|
||||
Âñ¸ ïîíÿòíî... Ñïàñèáî!
|
#7
|
|||
|
|||
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
|
#8
|
||||
|
||||
Êîðî÷å, òðåáóþòñÿ äîïîëíèòåëüíûå èññëåäîâàíèÿ... Âåðäèêò: íèçêàÿ ýôôåêòèâíîñòü?
|